ClinicalTrials.gg
Not yet recruitingNCT07943923Updated Nov 17, 2026

Multidomain Approach Through Biopsychosocial Pathways (MAP) Intervention for Older Adults With Age-Related Hearing Loss

An interventional study of Multidomain Approach through Biopsychosocial Pathways (MAP) intervention and Control group in Loneliness and Age-related Hearing Loss, sponsored by The Hong Kong Polytechnic University. Not yet recruiting. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by The Hong Kong Polytechnic University · Not applicable, Interventional, and Supportive care

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Study summary

Background With population aging accelerating worldwide, age-related hearing loss (ARHL) has become one of the most prevalent sensory impairments among older adults, with global prevalence rising from 12.7% at age 60 to over 58% by age 90. The communication difficulties, reduction in daily-life activities, and social stigma associated with hearing loss can contribute to increased loneliness in older adults. This condition affects approximately 25% of older adults in mainland China and 46% in Hong Kong and is associated with depression, increased mortality risk, and elevated healthcare utilization. Addressing loneliness in this population is therefore essential not only for older adults' own health and wellbeing, but also for promoting healthy aging and sustainable community-based care. However, limited studies have examined the associations between loneliness and physical, psychosocial, and hearing health status among older adults with ARHL in real-life living environments and no qualitative study has explored their perceptions and experiences of loneliness. The built environment may influence both hearing health and loneliness among older adults by shaping communication opportunities, social participation, mobility, and access to supportive resources. Therefore, examining the relationships among loneliness, hearing difficulties, and the built environment is important for understanding how everyday living contexts contribute to or mitigate loneliness in later life. Furthermore, existing intervention studies have concentrated mainly on hearing aids and cochlear implants. However, loneliness in this population arises not only from reduced auditory input, but also from psychological distress, social exclusion, and limited opportunities for social engagement, all of which are factors that hearing correction alone cannot directly resolve. These gaps limit the evidence base needed to understand and address loneliness in this population and hinder the development of multi-component interventions for older adults with ARHL.

Aim This study aims 1) to explore the perceptions and experiences of loneliness and social engagement among older adults with ARHL; 2) to examine the associations between loneliness and physical, psychosocial, hearing health, and built environment factors; and 3) to develop and preliminarily evaluate a Multidomain Approach through Biopsychosocial Pathways (MAP) intervention to address loneliness in this population.

Methods A sequential exploratory mixed methods design was adopted, underpinned by the Socio-Ecological Model. This study will be conducted in three phases. First, a qualitative descriptive methodology was used among community-dwelling older adults with ARHL to explore their perceptions and experiences of loneliness and social engagement. Second, a cross-sectional study, with GIS-based spatial analysis will be conducted to examine the associations between loneliness and physical, psychosocial, hearing health, and built-environment factors. Last, a pilot randomized controlled trial will be conducted to evaluate the feasibility, acceptability, and preliminary effects of MAP, underpinned by the biopsychosocial model and findings of previous phases to reduce loneliness among older adults with ARHL.

Expected outcomes This study is expected to 1) provide in-depth qualitative evidence on the perceptions and experiences of loneliness and social engagement among older adults with ARHL; 2) identify multilevel correlates of loneliness, spanning physical, psychosocial, hearing health, and built environment factors; 3) evaluate the feasibility, acceptability, and preliminary effects of MAP on loneliness, thereby informing the design of a future definitive trial and community-based service planning for this population.

02

Conditions studied

  • Loneliness
  • Age-related Hearing Loss

Browse trials for

03

In context

Presbycusis

67 studies on the registry are indexed under Presbycusis; 22 are open to participants now.

This study's planned enrollment of 60 is close to the median of 60 across 46 interventional studies indexed under Presbycusis.

Browse Presbycusis studies →

Lead sponsor

The Hong Kong Polytechnic University is the lead sponsor of 683 studies on the registry; 261 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. aged 60 years or older and living in the community;
  2. mild-to-moderate hearing loss, defined as a pure-tone average (PTA) of 20-50 dB across octave frequencies from 0.5 to 4 kHz in both ears;
  3. experiencing loneliness (De Jong Loneliness Scale score ≥ 3);
  4. willingness and ability to provide and comply with study procedures.

Exclusion criteria

Exclusion Criteria:

  1. a history of psychosis, mania, bipolar disorder, substance use disorder, or suicidal ideation;
  2. severe or unstable medical illness;
  3. significant retro cochlear pathology or an organic lesion causing hearing loss;
  4. a diagnosis of probable Alzheimer disease, vascular dementia, frontotemporal dementia, or Parkinson disease;
  5. regular engagement in mindfulness or other mind-body practices (>2 times weekly).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Multidomain Approach through Biopsychosocial Pathways (MAP) intervention

    The intervention group will receive a Multidomain Approach through Biopsychosocial Pathways (MAP) intervention comprising self-administered auricular acupressure, video-guided mindfulness practice adapted from Mindfulness-Based Stress Reduction (MBSR), and a GIS-guided community engagement programme, delivered concurrently over an 8-week period.

    Behavioral: Multidomain Approach through Biopsychosocial Pathways (MAP) intervention

  • Placebo comparator
    Control group

    The control group will receive reading materials on ARHL, loneliness, and hearing health education. The control group will receive delayed access to the Multidomain Approach through Biopsychosocial Pathways (MAP) intervention after completion of the final follow-up assessment.

    Behavioral: Control group

Interventions

  • BehavioralMultidomain Approach through Biopsychosocial Pathways (MAP) intervention

    The intervention group will receive a Multidomain Approach through Biopsychosocial Pathways (MAP) intervention comprising self-administered auricular acupressure, video-guided mindfulness practice adapted from Mindfulness-Based Stress Reduction (MBSR), and a GIS-guided community engagement programme, delivered concurrently over an 8-week period.

  • BehavioralControl group

    The control group will receive reading materials on ARHL, loneliness, and hearing health education. The control group will receive delayed access to the Multidomain Approach through Biopsychosocial Pathways (MAP) intervention after completion of the final follow-up assessment.

06

What researchers measure

Primary outcomes

  1. Adherence to the three intervention components

    Intervention adherence rates for the three components (Auricular acupressure self-administration, completion rate of weekly video-guided mindfulness sessions, and engagement with the GIS-guided community engagement programme) will be assessed using self-reported logs completed independently by older participants via paper booklets. For each component, adherence will be calculated as the number of completed sessions divided by the total number of prescribed sessions during the 8-week intervention period, multiplied by 100. Scores range from 0% to 100%, with higher percentages indicating greater adherence to the respective intervention schedule.

    Time frame: Throughout the 8-week intervention period

  2. Usage Frequency to the three intervention components

    The adherence to the three intervention components was assessed using self-reported logs completed independently by older participants via paper booklets. A usage session was defined as one recorded episode of engaging in each respective activity. Adherence for each component was quantified as the mean number of sessions completed per week across the 8-week intervention period, with higher values indicating more frequent engagement.

    Time frame: Throughout the 8-week intervention period

  3. Participant retention rate

    The participant retention rate will be calculated as the number of enrolled participants who remain in the study and have not withdrawn by Week 8 divided by the total number of participants enrolled, multiplied by 100. Scores range from 0% to 100%, with higher percentages indicating greater participant retention.

    Time frame: Week 8

  4. The follow-up assessment completion rate

    The follow-up assessment completion rate will be calculated as the number of participants who complete the scheduled Week 8 follow-up assessment divided by the total number of enrolled participants expected to complete the assessment, multiplied by 100. Scores range from 0% to 100%, with higher percentages indicating greater follow-up completion.

    Time frame: Week 8

  5. Acceptability of the intervention assessed by semi-structured interviews

    All participants in the intervention group will be invited to take part in an individual interview after completing the intervention, to explore their experiences of participating in the Multidomain Approach through Biopsychosocial Pathways (MAP) intervention and their perceptions of its acceptability. Interview data will be analyzed using thematic analysis and reported as themes and subthemes related to participants' experiences and perceived acceptability. No numerical scale score will be calculated.

    Time frame: Week 8, following completion of the intervention

Secondary outcomes

  1. Loneliness

    Loneliness will additionally be assessed as a preliminary indicator of intervention effect. This is the outcome proposed as the primary outcome for a future definitive trial. Change in loneliness from baseline to post-intervention will be measured using the Mandarin version of the 6-item De Jong Gierveld Loneliness Scale (DJGLS).

    Time frame: Baseline and Week 8

  2. Sleep quality

    Sleep quality will be assessed using the Chinese version of the Pittsburgh Sleep Quality Index (CPSQI), administered at baseline and post-intervention.

    Time frame: Baseline and Week 8

  3. Subjective hearing difficulty

    Subjective hearing difficulty will be measured using the 18-item Revised Hearing Handicap Inventory (R-HHI), administered at baseline and post-intervention.

    Time frame: Baseline and Week 8

  4. Depressive symptoms

    Depressive symptoms will be screened with the Patient Health Questionnaire-2 (PHQ-2), administered at baseline and post-intervention.

    Time frame: Baseline and Week 8

  5. Community resource utilization

    As no validated instrument exists for this intervention-specific component, a study-designed weekly tick-box log will be used to record visits to GIS-recommended resources (hearing service centers or community/green space facilities), with participants choosing a paper or electronic format based on preference. Logs will be submitted at the post-intervention assessment, with paper records transcribed into the same database as electronic entries. The primary metric will be the cumulative number of resource visits over the intervention period.

    Time frame: Baseline and Week 8

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Jan 2028, 13 months later.

Of 25 interventional studies with no phase under Presbycusis, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 58. This study's planned 13 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2026
First posted
Nov 17, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Jan 1, 2028
CompletionEst.
Jun 30, 2028
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07943923
Responsible party
Sponsor
First posted
Nov 17, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Jan 1, 2028 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
Nov 17, 2026

Study contacts

Ivy Yan Zhao
Contact
yan-ivy.zhao@polyu.edu.hk
+8527664550

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion